earningsconfidence high
Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026
Olema Pharmaceuticals, Inc.
2026-Q1 EPS
reported -$0.52
vs consensus -$0.54
▲ beat
(+3.6%)
- Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.
- Net loss Q1 2026: $53.1M vs $30.4M Q1 2025, driven by higher R&D spend.
- GAAP R&D expenses $49.2M (Q1 2026) vs $30.6M (Q1 2025); non-GAAP R&D $42.7M.
- Top-line data from pivotal Phase 3 OPERA-01 (palazestrant monotherapy) expected fall 2026.
- Initial Phase 1 data for OP-3136 to be presented at ASCO 2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.